Skip to content

Study · Ex vivo tissue · 2005

1 result

Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status.

Cooper A, Robinson SJ, Pickard C, Jackson CL, Friedmann PS, Healy E

Journal of immunology (Baltimore, Md. : 1950)1 Oct 2005Cited by 45 (Europe PMC)

PMID16177130 (opens in a new tab)DOI10.4049/jimmunol.175.7.4806 (opens in a new tab)PepBankPUB-16177130
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueEfficacy outcome

    In human PBMC assays depleted of monocytes or B lymphocytes, MTII inhibited antigen-induced lymphocyte proliferation.

    In plain wordsIn lab tests with human blood cells, MTII reduced the growth of immune cells triggered by an antigen.

    Peptide
    Melanotan II
    Outcome
    DecreaseAntigen-induced lymphocyte proliferation in monocyte-depleted and B lymphocyte-depleted assays
    Study

    humann: not reported in source

    human PBMC lymphocyte proliferation assays
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas alphaMSH and related analogs (SHU9119 and MTII) inhibited Ag-induced lymphocyte proliferation in monocyte-depleted and B lymphocyte-depleted assays
    1 context sentence
    Summary · context
    Here, we have investigated whether alphaMSH can suppress Ag-induced lymphocyte proliferation in humans and whether these effects are dependent on MC1R genotype. alphaMSH suppressed streptokinase-streptodornase-induced lymphocyte proliferation, with maximal inhibition at 10(-13)-10(-11) M alphaMSH.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.